Two recently approved treatments offer newfound hope for patients in the early stages of Alzheimer’s disease, but most people who could benefit will likely be deemed ineligible, a new study finds.
When those were factored in, the researchers discovered only 8% of the study participants would have been eligible for the Leqembi trial.
For Aduhelm , 44% of participants would have met the required characteristics, but after excluding for certain health issues, just 5% would have been eligible. He noted a consensus that's building in the field -- that appropriate use of medications should in many ways mirror the conditions under which the drug was tested in clinical trials.
The study offers very important information for clinicians, that a lot of the people who may seem eligible or may request treatment will not really be appropriate candidates for treatment, said Dr. Stephen Salloway, founding director of the Memory andSalloway is co-author of an editorial accompanying the study findings. Both were published Aug. 16 in the journalAmong the exclusions, Salloway noted that there is no evidence Leqembi works for people in the later stages of Alzheimer's disease.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Few patients may qualify to get new Alzheimer’s drugs, study suggestsLess than 1 in 10 patients with mild cognitive impairment or early-stage Alzheimer’s disease may be prescribed them.
Read more »
Black Angelenos CareA network for Alzheimer's patients and caregivers
Read more »
Black Angelenos Care for Alzheimer’s Patients — And Each OtherSupport groups help manage the strain on caregivers in the epicenter of Alzheimer’s cases.
Read more »
Bodybuilding Supplement HMB May Help Protect Memory and Stave Off Alzheimer’s DiseaseRUSH researchers found that HMB, a bodybuilding supplement, may help protect memory and prevent Alzheimer's disease progression. Studies in mice have demonstrated its potential effectiveness in reducing plaques and enhancing neuronal growth, signaling a promising avenue for Alzheimer's treatment. A
Read more »
Northwestern Medicine shares new findings from ongoing COVID studyNorthwestern has been studying patients at its Comprehensive COVID-19 Center since May 2020.
Read more »
Company Town BlogA blog about the entertainment business (May 2008 - May 2012)
Read more »